Allison Keely Pribnow, MD
Pediatric Hematology-Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Pribnow’s office at (650) 497-8000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A122020 · Current
Licensed to practise in California · since 2012 · expires 2028-01-31 · Oregon Health Sciences University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Pediatrics - Pediatric Hematology-Oncology
- American Board of Pediatrics - Pediatrics
Medicaid work
$40,479 in 2024
Medicaid paid $40,479 for 207 billed services this clinician did in 2024, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 207 | $40,479 |
| 2024 | 207 | 1 | 18 | $40,479 |
| 2023 | 288 | 2 | 21 | $42,445 |
| 2020 | 46 | 1 | 15 | $3,726 |
| 2019 | 104 | 1 | 16 | $7,883 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 249 | $39,364 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 39 | $3,081 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 46 | $3,726 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 104 | $7,883 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Ipsen Biopharmaceuticals, Inc · A Randomized Phase I/II Study of Onivyde in Combination With Talazoparib Or Temozolomide in Children With Recurrent Solid Malignancies and Ewing Sarcoma · 2024 | Their institution | $110,640 |
| JAZZ PHARMACEUTICALS INC. · Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed, ?Refractory Ewing Sarcoma · 2024 | Their institution | $55,485 |
| PFIZER INC. · A Randomized Phase I and II Study of Onivyde in Combination With Talazoparib Or Temozolomide in Children and Young Adults With Recurrent Solid Malignancies and Ewing Sarcoma · 2024 | Their institution | $28,750 |
| Ipsen Innovation · A Phase II, Randomized, Open-Label Study To Assess the Efficacy, Safety, and Pharmacokinetics (Pk) of Maintenance Cabozantinib (Xl184) Plus Best Supportive Care (Bsc) Versus Bsc in Children, Adolescents and Young Adults (Aya) With Unresectable Residual Osteosarcoma Either at Diagnosis Or at First Relapse After Standard Treatment · 2025 | Their institution | $28,395 |
| JAZZ PHARMACEUTICALS INC. · A Phase 1/2, Open-Label Study To Evaluate the Safety, Tolerability, Pharmacokinetics (Pk), Recommended Phase 2 Dose (Rp2d), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants With Previously Treated Solid Tumors Followed By Expansion To Assess Efficacy and Safety in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma. · 2024 | Their institution | $369 |
| JAZZ PHARMACEUTICALS INC. · A Phase 1/2, Open-Label Study To Evaluate the Safety, Tolerability, Pharmacokinetics (Pk), Recommended Phase 2 Dose (Rp2d), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants With Previously Treated Solid Tumors Followed By Expansion To Assess Efficacy and Safety in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma. · 2025 | Their institution | $165 |
Professional record
- NPI
- 1386939296
- Licence
- CA A122020California A122020: Current · expires 2028-01-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X); Pediatrics (208000000X)
- Mailing address
- 1000 Welch Rd Ste 300, Palo Alto, CA, 94304
- NPI first listed
- 2011-06-20
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.